Mario Castro, MD
Pulmonary Disease · Kansas City, KSNPI 1881610004
Payments from drug & device makers
Across 1,544 payments — averaging $2474.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$877K
- AstraZeneca$854K
- Galvanize Therapeutics, Inc$621K
- Regeneron Healthcare Solutions, Inc.$245K
- Sanofi US Services Inc.$234K
- Astrazeneca UK Limited$234K
- plus $756K from 22 others
Across 188 payments — averaging $443.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$42K
- Sanofi-aventis U.S. LLC$38K
- Teva Pharmaceuticals USA, Inc.$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 460 | $876,537 |
| AstraZeneca | 441 | $853,784 |
| Galvanize Therapeutics, Inc | 12 | $621,317 |
| Regeneron Healthcare Solutions, Inc. | 207 | $245,135 |
| Sanofi US Services Inc. | 52 | $234,157 |
| Astrazeneca UK Limited | 14 | $233,910 |
| Regeneron | 71 | $220,208 |
| Teva Pharmaceuticals USA, Inc. | 112 | $198,155 |
| GSK | 40 | $68,991 |
| Novartis | 10 | $48,672 |
| Sanofi-aventis U.S. LLC | 13 | $39,578 |
| Genentech USA, Inc. | 27 | $30,578 |
| Amgen | 25 | $30,147 |
| Pfizer | 8 | $28,895 |
| Shionogi Inc | 8 | $21,731 |
| Merck | 16 | $21,134 |
| Boehringer Ingelheim | 2 | $18,429 |
| Sanofi Pasteur Inc. | 4 | $13,813 |
| Polarean, Inc. | 9 | $6,007 |
| Mylan Specialty L.p. | 5 | $5,768 |
| Chiesi USA, Inc. | 1 | $3,000 |
| Mylan Inc. | 1 | $436 |
| Siemens Medical Solutions USA, Inc. | 1 | $167 |
| Biocryst US Sales Co., LLC | 1 | $148 |
| Incyte Corporation | 1 | $60 |
| Atricure, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $14 |
| Electromed, Inc. | 1 | $13 |
How this compares
$3,820,804 in reported general payments places this provider in the 95th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Kansas City
- Andreas SchmidKansas City$2M
- Sahil PandyaKansas City$1.1M
- Matthew SharpeKansas City$602K
- Joel MermisKansas City$360K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Damien StevensKansas City$208K
- Heath LathamKansas City$174K
- Harold BarkmanKansas City$24K
- Kyle BrownbackKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.